Cue Health and Everlywell are eyeing billion-dollar valuations for their at-home diagnostic solutions.

A primer on why recent vaccine news matters and what challenges remain.

Amazon-branded pills

*sunglasses emoji* Dentists are cool now.

President Trump is receiving experimental treatment from Regeneron, a pharma firm defined by the partnership between two doctors.

Virtual primary care apps, at-home diagnostics and caregiver training are all opportunities primed to grow if the current uptake in telemedicine continues.

Etsy’s army is working overtime.

Lockdowns are disrupting the contraceptive supply chain. But don’t expect a baby boom.

Next Move is one of the rare companies that is seeing business take off, but its founder has to be frank with people who want to help.

Thanks to various technologies, doctors are consulting videos and VR more than ever -- but not all patients are comfortable with that.

11 biotech companies have filed for bankruptcy so far this year, making 2019 the worst year for biotech in a decade.

FDA approval of the world’s most expensive drug sparks hope for SMA patients... and debate over healthcare costs.

Prices for insulin have skyrocketed, and it’s up to the three companies who own the entire market to voluntarily lower them… spoiler alert: they aren’t.

Natural Cycles gets its Facebook ad removed by the UK regulatory system for being ‘misleading’ to customers.

As CEO pay packages continue to rise, shareholders are starting to pick up their pitchforks when executive bonuses don’t line up with corporate performance.

After dodging numerous attempts at regulation, the company that makes EpiPens has kept its competitors so small that they can’t even address the current supply backlog.